Phase 3 Readout
OCGN: Phase 3 Topline: A PHASE 1 STUDY TO ASSESS THE SAFETY AND EFFICACY OF OCU410ST FOR STARGARDT DISEASE AND PHASE 2/3 PI
September 28, 2026. BioSniper AI can trace the company-impact path without requiring you to write the research question.
- Event date
- September 28, 2026
- Company
- Ocugen, Inc. (OCGN)
BioSniper AIPage evidence connected
Prepared research question
What could this event change, and which evidence should be watched next?
Run cited research
Traceable citations · Unknowns marked
Phase 3 Readout~month
Phase 3 Topline: A PHASE 1 STUDY TO ASSESS THE SAFETY AND EFFICACY OF OCU410ST FOR STARGARDT DISEASE AND PHASE 2/3 PI
- Company
- Ocugen, Inc. (OCGN)
- Indication
- Stargardt Disease